Citigroup’s Rubius Therapeutics RUBY Stock Holding History
Bought
Maintained
Sold
Other funds holding RUBY
AG
Citigroup's RUBY Position: Q1 2023 in Review
Citigroup sold out of Rubius Therapeutics (RUBY) in Q1 2023, closing a stake of 1,342 shares — an estimated $231 sold.
Citigroup first reported a position in RUBY in Q3 2018 and held it in 17 quarters. The position peaked at $4.54M in Q2 2021. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.
- Citigroup reported no remaining Rubius Therapeutics position as of Q1 2023 after selling out during the quarter.
- Citigroup sold 1,342 Rubius Therapeutics shares in Q1 2023, an estimated $231.
- Citigroup first reported a position in Rubius Therapeutics in Q3 2018 and held it in 17 quarters.
- Citigroup's Rubius Therapeutics position peaked at $4.54M in Q2 2021.
- 7 funds tracked by Wall St. Rank held Rubius Therapeutics as of Q1 2023.
Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.